

# **Co-expression patterns define epigenetic regulators associated with neurological dysfunction**

---

**Kasper Daniel Hansen**

< [khansen@jhsph.edu](mailto:khansen@jhsph.edu) | [www.hansenlab.org](http://www.hansenlab.org) >

Department of Biostatistics

McKusick-Nathans Institute of Genetic Medicine

Johns Hopkins University


# Genetics

---

Genome (DNA)  Phenotype

# Epigenetics (transcriptomics)

---



# Mendelian disorders of the epigenetic machinery

EM: genes involved in DNA methylation or histone modifications




(hypothesis)

Recent interest in the epigenetic machinery

**Cancer:** Somatic mutations in EM genes are frequent in many cancers.

**Neurological:** GWAS and rare variant analysis has implicated EM genes in various neurological disorders incl. sz. and autism.

# Shared phenotypes in EM disorders



# Kabuki syndrome / intervening on the epigenome

Caused by LOF in KMT2D or KDM6A.

Can the intellectual disability associated with Kabuki syndrome be reversed by changing the epigenome?

The answer is yes

(caveats: short-term, in mice, Kabuki type I)

1. (with HDACi): “Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome” Bjornsson et al (2014) Sci Trans Med.
2. (with diet): “A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome”, Benjamin et al (2017) PNAS.

# Questions

---

1. Characterize the EM
2. Is the epigenetic function of the EM genes, the most likely cause of disease?
3. Are there expression signatures characteristic of disease candidates?
4. Are there distinct expression signatures between the EM genes involved in neurological dysfunction and cancer?

## **Co-expression patterns define epigenetic regulators associated with neurological dysfunction**

Leandros Boukas, James M Havrilla,  Aaron R Quinlan,  Hans T Bjornsson,  Kasper D Hansen


**doi:** <https://doi.org/10.1101/219097>

# Defining the Epigenetic Machinery using protein domains

Any gene encoding a protein with a domain which can act as



- Reader / Writer / Eraser of DNA methylation.
- Reader / Writer / Eraser of histone methylation / acetylation.
- Chromatin remodeler

295 EM genes



# Loss of function (LOF) mutations


We have two copies of each gene.  
Each copy produces mRNA at the same rate



“dosage sensitive” or “haploinsufficient”

# EM genes are highly intolerant to LOF mutations


---



Using ExAC (Lek et al. 2016)


# EM genes are very intolerant to LOF mutations

---



# EM genes are very intolerant to LOF mutations

---




# The epigenetic machinery and tissue expression

---


These epigenetic marks are present in every cell type and at every time point.

Genetic defects act in every cell where the gene is expressed.

The GTEx (genotype-tissue expression) project is profiling ~30 tissues in ~1000 people.





# Testis is an outlier tissue





Gene name	Testis specificity score
<i>PRDM9</i>	1
<i>PRDM13</i>	1
<i>PRDM14</i>	1
<i>CDY2A</i>	1
<i>BRDT</i>	0.87
<i>RNF17</i>	0.86
<i>HDGFL1</i>	0.81
<i>PRDM7</i>	0.77
<i>MORC1</i>	0.75
<i>TDRD15</i>	0.67
<i>TDRD1</i>	0.52

# Motivation for co-expression

1 tissue in GTEx




All of GTEx




# Co-expression; tissue-specific networks and modules

Tissue 1




Tissue 2



•  
•  
•

Tissue 28



# Removing unwanted variation in co-expression networks

## Addressing confounding artifacts in reconstruction of gene co-expression networks

 Princy Parsana, Claire Ruberman, Andrew E. Jaffe, Michael C. Schatz, Alexis Battle, Jeffery T. Leek

doi: <https://doi.org/10.1101/202903>

Simple solution: remove the top singular values; they will represent artifacts

RESEARCH ARTICLE

Open Access


Systematic noise degrades gene co-expression signals but can be corrected




Saskia Freytag<sup>1,2\*</sup>, Johann Gagnon-Bartsch<sup>3</sup>, Terence P. Speed<sup>1,2,3</sup> and Melanie Bahlo<sup>1,2,4</sup>

How do we measure if it works?

# Random groups of genes




# Positive controls




# Co-expression; tissue-specific networks and modules


Tissue 1





Tissue 2



Tissue 28




Module partners across tissues




Number of partners

120  
70  
20





# Co-expression is associated with LOF intolerance


---




# Co-expression is associated with LOF intolerance






# Permutations



# Co-expression is associated with LOF intolerance



# Co-expression is associated with neurological dysfunction



# Acknowledgements

---



Leandros Boukas



James Havrilla



Hans Bjornsson



Aaron Quinlan

## **Co-expression patterns define epigenetic regulators associated with neurological dysfunction**

Leandros Boukas, James M Havrilla,  Aaron R Quinlan,  Hans T Bjornsson,  Kasper D Hansen

**doi:** <https://doi.org/10.1101/219097>

(looking for postdocs)

# Domains

